[ORGANIZATION]
Ocugen
Featured in 5 tracked stories · first seen
Situations
Ocugen OCU400 development and licensing
2 clusters · 4 sources · last updated
Latest: Ocugen secures licensing deal and outlines OCU400 timeline
Ocugen is advancing its gene therapy candidate, OCU400, which is designed to treat retinitis pigmentosa. In September 2026, the company received provisional authorization and priority status from the Longevity and Regene
Ocugen clinical trial results and market performance
2 clusters · 6 sources · last updated
Latest: Ocugen earnings estimates raised as Oculis board member resigns
Ocugen experienced significant market volatility following an interim analysis of its OCU410ST gene therapy study for Stargardt disease. Data from the first 26 participants indicated a “negative treatment effect,” causin
Also covered in
-
Scientific innovations in bionics and biotechnology highlighted
[BUSINESS] · 2 sources ·